Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayhill Therapeutics Inc.

This article was originally published in Start Up

Executive Summary

By using DNA that encodes for self-antigens, Bayhill Therapeutics hopes to dampen or terminate the activities of TH1 helper cells involved in tissue destruction in autoimmune diseases, specifically multiple sclerosis, while at the same time activating TH2 cells to help combat the disease.
Advertisement

Related Content

New Approaches to Treating Autoimmune Diseases
A Precarious Union: Combining Proprietary and Generic Businesses
A Precarious Union: Combining Proprietary and Generic Businesses

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC090791

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel